Europe Finance Weekly
SEE OTHER BRANDS

Fresh finance and banking news from Europe

Europe Finance Weekly: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Europe Finance Weekly.

Press releases published on May 8, 2025

BigCommerce Announces First Quarter 2025 Financial Results

BigCommerce Announces First Quarter 2025 Financial Results

AUSTIN, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- BigCommerce Holdings, Inc. (“BigCommerce” or the “Company”) (Nasdaq: BIGC), an open SaaS, composable ecommerce platform for fast-growing and established B2C and B2B brands, retailers, manufacturers and …

Abcourt Intersects 24.3 g/t Over 1.9 m Including 41.9 g/t Over 0.6 m in the 785N Zone and Provides an Update on Its Sleeping Giant Activities

Abcourt Intersects 24.3 g/t Over 1.9 m Including 41.9 g/t Over 0.6 m in the 785N Zone and Provides an Update on Its Sleeping Giant Activities

ROUYN-NORANDA, Quebec, May 08, 2025 (GLOBE NEWSWIRE) -- Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) (OTCQB: ABMBF) is pleased to report new drilling results and an update on its activities at the Sleeping Giant mine. In 2025, …

ChampionX Declares Quarterly Dividend

ChampionX Declares Quarterly Dividend

THE WOODLANDS, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- ChampionX Corporation (Nasdaq: CHX) (“ChampionX”) announced today its Board of Directors has declared a regular quarterly dividend of $0.095 per share on the company’s common stock, par value $0.01 per …

Supremex Announces Results for the First Quarter of 2025 and its Intention to Renew Normal Course Issuer Bid (“NCIB”)

Supremex Announces Results for the First Quarter of 2025 and its Intention to Renew Normal Course Issuer Bid (“NCIB”)

MONTREAL, May 08, 2025 (GLOBE NEWSWIRE) -- Supremex Inc. (“Supremex” or the “Company”) (TSX: SXP), a leading North American manufacturer and marketer of envelopes and a growing provider of paper-based packaging solutions, today announced its results for …

Supremex annonce des résultats pour le T1 2025 et son intention de renouveler son offre publique de rachat (« OPR »)

Supremex annonce des résultats pour le T1 2025 et son intention de renouveler son offre publique de rachat (« OPR »)

MONTRÉAL, 08 mai 2025 (GLOBE NEWSWIRE) -- Supremex inc. (« Supremex » ou la « Société ») (TSX : SXP), chef de file nord‑américain dans la fabrication et la distribution d’enveloppes ainsi qu’un fournisseur de solutions d’emballage en plein essor, annonce …

Apyx Medical Corporation Reports First Quarter 2025 Financial Results

Apyx Medical Corporation Reports First Quarter 2025 Financial Results

Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last year U.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last year Preparing for a planned launch of the AYON™ Body …

Willis Lease Finance Corporation Moves its Consultancy and Advisory Arm to Willis Mitsui & Co. Engine Support Limited

Willis Lease Finance Corporation Moves its Consultancy and Advisory Arm to Willis Mitsui & Co. Engine Support Limited

COCONUT CREEK, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC” or the “Company”), the leading lessor of commercial aircraft engines and global provider of aviation services, today announced it has entered into …

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial Preliminary data from Phase 2 trial of Descartes-08 in …

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking to build on the clinical activity and tolerability …

Aduro Clean Technologies and Cleanfarms Sign Memorandum of Understanding to Collaborate on Development of Commercial Pathway for Challenging Agricultural Plastics

Aduro Clean Technologies and Cleanfarms Sign Memorandum of Understanding to Collaborate on Development of Commercial Pathway for Challenging Agricultural Plastics

LONDON, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower-value feedstocks, like waste …

OTC Markets Group Welcomes Black Swan Graphene Inc. to OTCQX

OTC Markets Group Welcomes Black Swan Graphene Inc. to OTCQX

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Black Swan Graphene Inc. (“Black Swan”) (TSX-V: SWAN; OTCQX: BSWGF), a …

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren’s disease; Phase 1 study in active, moderate to severe patients …

Peloton Interactive, Inc. Reports Third Quarter Fiscal 2025 Financial Results

Peloton Interactive, Inc. Reports Third Quarter Fiscal 2025 Financial Results

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Peloton Interactive, Inc. (Nasdaq: PTON) has announced its financial results for the third quarter of fiscal 2025. Please visit the Peloton investor relations website to view the shareholder letter. Today, the …

Berry Corporation Reports First Quarter 2025 Financial and Operational Results, Reaffirms FY25 Guidance and Announces Quarterly Dividend

Berry Corporation Reports First Quarter 2025 Financial and Operational Results, Reaffirms FY25 Guidance and Announces Quarterly Dividend

DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Berry Corporation (bry) (NASDAQ: BRY) (“Berry” or the “Company”) today announced its financial and operational results for the first quarter of 2025, as well as a quarterly cash dividend of $0.03 per share. Berry …

Lee Enterprises Reports Second Quarter Results

Lee Enterprises Reports Second Quarter Results

Total Digital Revenue(1) of $73M represented 53% of total revenue Digital-Only subscription revenue increased 20% YOY(2)  Amplified Digital® Agency revenue totaled $25M, or up 9% YOY(2) DAVENPORT, Iowa, May 08, 2025 (GLOBE NEWSWIRE) -- Lee Enterprises, …

Cielo Issues Letter to Shareholders

Cielo Issues Letter to Shareholders

CALGARY, Alberta, May 08, 2025 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV: CMC; OTC PINK: CWSFF) (“Cielo” or the “Company”) is pleased to have issued today a letter to shareholders, as below: Dear Shareholders, Thank you to all those who …

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 million Bolstered balance sheet and expanded institutional investor ownership …

Ligand Reports First Quarter 2025 Financial Results

Ligand Reports First Quarter 2025 Financial Results

First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $ …

Aptose Reports First Quarter 2025 Results

Aptose Reports First Quarter 2025 Results

SAN DIEGO and TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat …

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline results expected in the third quarter of 2025 RAP-219 Phase 2a trial in patients with bipolar mania remains on track to commence in the third quarter of 2025, …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service